To prevent or delay acquired resistance to EGFR-TKIs and prolong overall survival, combining EGFR-TKIs with other anti-tumor therapies, such as antiangiogenic agents or chemotherapy, is a rational strategy [19]. The gene discussed is EGFR; the disease is neoplasm.